CD8A and neoplasm: Moreover, lenalidomide, an IKZF1/3 degrader, combined with R‐CHOP, improves the poor prognosis of A7 DLBCL patients by boosting T‐cell trafficking and MHC expression, promoting CD8+ T‐cell recognition of tumor cells.46